Cassava Sciences Inc vs Range Nuclear Renaissance ETF — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Range Nuclear Renaissance ETF trades at $61.26 (market cap $698.21M). The key difference: Range Nuclear Renaissance ETF is far larger — about 17.7× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 57,444). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Range Nuclear Renaissance ETF for 18 Days on average.
| FLNA | NUKZ | |
|---|---|---|
Market Cap | $39.40M | $698.21M |
Volume | 759,018 | 57,444 |
Sector | Health | Sector/Thematic |
52-Week High | $4.64 | $76.23 |
52-Week Low | $0.68 | $60.23 |
Typical Hold Time | 37 Days | 18 Days |
Enterprise Value | -$43.28M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8168 with minimal daily movement (+0.13%). The stock shows bearish technical signals with negative moving averages but has beaten earnings expectations for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam enables Phase 2a epilepsy trials, providing potential catalyst. However, the company reports zero revenue, negative EBITDA of -$95.19M, and concerning cash flow trends with net cash outflow of -$33.07M in 2025.
While analyst consensus is strongly bullish (67% buy ratings), fundamental weaknesses including negative profitability metrics and cash burn present significant risks. The FDA approval provides near-term optimism for the epilepsy drug pipeline, but execution risk remains high given the company's financial position and lack of current revenue streams.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Range Nuclear Renaissance ETF seeks to track companies related to the nuclear energy industry. Its holdings may include businesses involved in uranium, nuclear power generation, reactors, and nuclear services.
Read more on NUKZ →